Outlook Therapeutics (OTLK) Current Assets (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Current Assets of $20.9 million for Q1 2026, up 17.4% year-over-year from $17.8 million in Q1 2025, and up 21.78% quarter-over-quarter from $17.2 million in Q4 2025.
Outlook Therapeutics (OTLK) Current Assets (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Current Assets for 12 consecutive years, with $20.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 17.4% year-over-year to $20.9 million; the TTM figure through Mar 2026 stood at $20.9 million (up 17.4% YoY), while the FY2025 annual figure was $17.4 million, down 36.57% from the prior year.
- Current Assets improved to $20.9 million in Q1 2026 per OTLK's latest filing, from $17.2 million in the prior quarter.
- Across five years, Current Assets topped out at $66.5 million in Q1 2022 and bottomed at $15.7 million in Q4 2024.
- Historically, Current Assets has averaged $34.2 million across 5 years, with a median of $27.5 million in 2022.
- Annual changes were most pronounced in 2022 — Current Assets jumped 51.96% — and 2025, when it plunged 69.18%.
- Outlook Therapeutics' Current Assets stood at $61.7 million in 2022, then sank by 66.94% to $20.4 million in 2023, then fell by 23.16% to $15.7 million in 2024, then increased by 9.57% to $17.2 million in 2025, then advanced by 21.78% to $20.9 million in 2026.
- Business Quant data shows OTLK's Current Assets at $20.9 million in Q1 2026, $17.2 million in Q4 2025, and $17.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 1.76 Bn |
| 10 | Outlook Therapeutics | 95.08 Mn | 83.84 Mn | -8,265.00 | 23.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.90 Mn |
| Dec 31, 2025 | 17.17 Mn |
| Sep 30, 2025 | 17.39 Mn |
| Jun 30, 2025 | 21.10 Mn |
| Mar 31, 2025 | 17.81 Mn |
| Dec 31, 2024 | 15.67 Mn |
| Sep 30, 2024 | 27.42 Mn |
| Jun 30, 2024 | 45.62 Mn |
| Mar 31, 2024 | 57.79 Mn |
| Dec 31, 2023 | 20.39 Mn |
| Sep 30, 2023 | 30.98 Mn |
| Jun 30, 2023 | 43.02 Mn |
| Mar 31, 2023 | 53.05 Mn |
| Dec 31, 2022 | 61.68 Mn |
| Sep 30, 2022 | 27.52 Mn |
| Jun 30, 2022 | 37.51 Mn |
| Mar 31, 2022 | 66.55 Mn |
| Dec 31, 2021 | 77.47 Mn |
| Sep 30, 2021 | 21.51 Mn |
| Jun 30, 2021 | 31.90 Mn |